

## Press Release

**Martin Kunze**  
Corporate Communications

Fresenius SE & Co. KGaA  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Germany  
T +49 6172 608-2115  
F +49 6172 608-2294  
martin.kunze@fresenius.com  
www.fresenius.com

February 9, 2021

### **Fresenius Kabi expands facilities in Austria**

Fresenius Kabi is further expanding its Austrian facilities. The company will invest more than €60 million through 2023 to expand capacity and upgrade infrastructure at its production plant in Graz and packaging center in nearby Werndorf. The measures will be focused on the freeze-drying area and the lines for filling and packing glass bottles and ready-to-administer prefilled syringes.

“Prefilled syringes are a fast-growing market for us,” said Plant Manager Dr. Ruth Staubmann. “Many healthcare institutions and organizations recognize the clear advantages in terms of their rapid application and, above all, safety of use.” The expansion of the Graz plant will approximately double production capacity in this product category.

Fresenius Kabi produces liquid pharmaceuticals and clinical nutrition products for the Austrian and international markets in Graz. The site has special expertise in aseptic production and the manufacturing of complex products such as anesthetics, analgesics, anti-infectives and antibiotics. It also makes clinical nutrition products. In total, Fresenius Kabi currently has more than 900 employees in Graz. The number of additional jobs that will be created through the expansion cannot yet be determined.

In addition to the Graz plant and the packaging and logistics center in Werndorf, Fresenius Kabi’s Austrian operations include a research and development center in Grambach and a plant and distribution facility in Linz that specializes in the

production of active ingredients and lactulose. The company employs a total of about 1,500 people in Austria.

# # #

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.

Fresenius Kabi employs around 40,000 people worldwide. In 2019, the company reported sales of more than €6.9 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

For more information visit the Company's website at [www.fresenius-kabi.com](http://www.fresenius-kabi.com)

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Management Board: Mats Henriksson (Chairman), Marc Crouton, John Ducker, Dr. Oskar Haszonits, Dr. Christian Hauer, Dr. Michael Schönhofen, Gerrit Steen  
Chairman of the Supervisory Board: Stephan Sturm  
Registered Office: Bad Homburg, Germany  
Commercial Register: Amtsgericht Bad Homburg - HRB 11654